Botulinum Toxin for Frown Lines: Reading the Evidence Behind the Marketing

Randomized, placebo-controlled trials show that botulinum toxin type A reliably softens moderate to severe frown lines for most treated adults at roughly one month after injection, and the effect over placebo is large and consistent across products. That much the evidence establishes cleanly. The harder question is what the advertised numbers mean, because a "responder rate" depends entirely on how a study defined a responder, and because a small but documented risk of temporary eyelid droop rarely shares equal billing with the before-and-after photos.

What the frown-line trials actually measured

The frown lines between the eyebrows are called glabellar lines, produced mainly by the corrugator and procerus muscles. The pivotal trials that support product labels enrolled adults with moderate to severe lines and randomized them to a single treatment or to placebo injections, then graded the result at about day 30.

Two things stand out in how these studies scored success. First, severity was rated on a short ordinal scale, typically 0 (none) to 3 (severe). Second, most trials used two co-primary endpoints rather than one: an investigator's rating of line severity at maximum frown, and the subject's own global assessment of change. The FDA label for onabotulinumtoxinA (BOTOX Cosmetic) spells out the definitions plainly. On the investigator scale a responder was someone who reached a severity grade of 0 or 1 at maximum frown, and on the subject scale a responder needed to report at least a +2, described as moderate improvement, on a scale running from +4 to -4. Those are the thresholds behind the marketing percentages.

Why the definition changes the headline number

A responder rate is not a fact about a drug; it is a fact about a cutoff. Requiring a patient to drop from severe all the way to "none or mild" is a stricter bar than requiring a one-grade improvement, and it produces a smaller headline number from the same data. When two products quote different response percentages, part of the gap can be the endpoint, the timepoint, or the frown condition (at rest versus at maximum frown), not the molecule. This is the first place a careful reader separates evidence from advertising: ask what counted as a response, at what timepoint, and measured by whom.

What the pooled evidence establishes against placebo

The direction and size of the effect are not in serious doubt. A 2023 network meta-analysis in Aesthetic Plastic Surgery pooled randomized controlled trials of five botulinum toxin type A formulations for glabellar lines and found that every formulation significantly outperformed placebo on the standard response endpoints, while reporting comparable treatment-related adverse event profiles across the products. A separate 2026 systematic review and meta-analysis in Aesthetic Surgery Journal Open Forum, which applied the GRADE framework to three phase III placebo-controlled trials of incobotulinumtoxinA for the upper face, found that the proportion of patients reaching at least a one-grade improvement at day 30 was overwhelmingly higher with active treatment than placebo across the glabella, forehead, and crow's-feet regions.

Two cautions belong next to those results. Very large relative effects, such as a risk ratio in the double digits, look dramatic partly because so few placebo patients improve on their own; a relative measure inflates when the comparator rate is near zero. And efficacy is anchored to a specific window. These are single-treatment readouts around one month in adults selected for moderate to severe lines, not a statement about how a given person will look at month four or after repeated cycles.

Weighing the adverse events, especially eyelid droop

The most-scrutinized local adverse event is blepharoptosis, a temporary drooping of the upper eyelid that occurs when the toxin diffuses to the muscle that raises the lid. It is worth looking at exactly how the pivotal data describe it. The onabotulinumtoxinA label reported blepharoptosis in about 3 percent of treated subjects versus none on placebo in the original trials, and in a repeat-injection study the rate was around 2 percent in the first cycle and 1 percent in the second. In the incobotulinumtoxinA meta-analysis, the pooled data reported brow ptosis, a droop of the eyebrow that is distinct from eyelid droop, as numerically higher with active treatment but not statistically different from placebo, while serious adverse events were rare and none were judged treatment-related.

Read together, those figures point to a low-single-digit, generally transient risk rather than either zero or a common outcome. A claim that a product is "complication-free" is not what the labels say; a claim that eyelid droop is frequent overstates it. The honest summary is a small, real, usually self-limited risk that a reasonable person can weigh against a cosmetic benefit. How much that risk matters is an individual judgment, and it is one to make with a qualified clinician who can examine the specific case, not from a blog. This article is educational and is not medical advice.

How to read the next product claim

A few questions cut through most marketing. What was the responder definition, and at which timepoint? Was the comparator placebo or another active product, and if a product looks "superior," is that a head-to-head trial or an indirect network comparison? Does the safety line quote the actual labeled adverse-event range, including blepharoptosis, or does it simply go quiet? A claim can legally describe what a trial showed in the studied population; it cannot legally promise you a specific result. The trials establish that these drugs work against placebo for glabellar lines, on defined endpoints, with a modest and characterized risk profile. Everything past that boundary is where evidence ends and persuasion begins.